Latest Industrial Scale Up News

ClearVue Technologies has developed a unique manufacturing capability allowing its Gen 3 Vision Glass to have soft high-performance Low-E coatings applied on surface 4, the optimal position for solar heat control, after photovoltaic cells are laminated. This breakthrough enhances thermal performance and expands commercial façade market access globally.

Anson Resources has dramatically expanded its Green River Lithium Project resource and confirmed robust project economics, while sealing a key agreement with POSCO for a demonstration plant funded by the Korean industrial giant.

Parkway Corporate delivered a record $7.25 million quarterly revenue and $0.54 million EBITDA, powered by a major water infrastructure contract. The company progressed key approvals for its Queensland Brine Management Complex and struck a strategic collaboration with Hitachi to develop advanced brine concentration technology.

X2M Connect has secured $2 million in a placement to boost its data centre and AI energy management platform, with a fully underwritten $1 million Securities Purchase Plan to follow. The capital raise supports sensor integration, platform enhancements, and battery energy systems aimed at cutting data centre precinct energy costs by up to 20%.

Adisyn has confirmed a repeatable, industrial-scale graphene deposition process compatible with semiconductor manufacturing temperatures, while advancing exclusive radar absorption technology for drones with major partners.

Cadoux Ltd and the SAFELOOP consortium have surpassed key performance and recycling targets in lithium-ion battery development, marking a world-first in commercial-scale use of recycled active materials enhanced by Cadoux's premiumHPA®. This breakthrough advances the pathway to gigafactory production and strengthens Cadoux's position in the EV battery supply chain.

Titomic Limited updates investors that its planned shift of corporate domicile from Australia to the US is still underway but the timeline has slipped, with a revised schedule expected by late July or August 2026.

Mesoblast has completed treatment of 300 patients in its pivotal Phase 3 trial for rexlemestrocel-L, targeting chronic low back pain due to degenerative disc disease, with topline results expected mid-2027.

Mesoblast Limited’s Ryoncil® posted US$36 million in Q4 revenue, driving a full-year total of US$115 million, exceeding initial forecasts. The FDA-approved stem cell therapy for pediatric graft-versus-host disease shows robust uptake across US pediatric centres.

Wide Open Agriculture is closing its German plant and pivoting to contract manufacturing in Asia to cut costs and scale lupin ingredient production efficiently under new CEO Craig Swan.

Mesoblast has received a Biologics License Application filing number from the FDA for rexlemestrocel-L, targeting life-threatening bleeding in end-stage heart failure patients with LVADs, advancing its regulatory journey with orphan drug and RMAT designations.

Mesoblast has drawn US$50 million from a new five-year facility that reduces its interest burden and retires expensive short-term debt, strengthening its financial position ahead of commercial expansion.